Drugs / ETX-636
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06993844 | Jun 2025 → Jun 2027 expected | breast cancer | Ensem Therapeutics | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ETX-636 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06993844 ↗ |
| Action | Inhibit | “ETX-636 is a pan-mutant-selective PI3Kα Inhibitor and degrader” NCT06993844 ↗ |
| Route | Oral | “ETX-636 is a pan-mutant-selective PI3Kα Inhibitor and degrader in the form of an oral tablet” NCT06993844 ↗ |